Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17139 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, 2024. Written by Ashley S Parker and 4 co-authors. Institution: Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA. Major MEDLINE topics: Dog Diseases, Vincristine, Cyclophosphamide, Antineoplastic Combined Chemotherapy Protocols. Cited 4 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: FDA HHS, VetDC, Inc, U.S. Food and Drug Administration.
Topics: Onkologische Pflege
Abstract (original language)
Background
Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy.
Objective
Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy.
Methods
Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase.
Results
The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB.
Conclusion
Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.
- Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA.
- Red River Animal Emergency Hospital & Referral Center, Fargo, North Dakota, USA.
ORCID profiles: Ashley S Parker, Jenna H Burton, Douglas H Thamm
Funding
- FDA HHS
- VetDC, Inc
- U.S. Food and Drug Administration
- Elanco Animal Health
Cite
APA
Parker, A. S., Burton, J. H., Curran, K. M., Wolf-Ringwall, A., & Thamm, D. H. (2024). Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17139
Vancouver
Parker AS, Burton JH, Curran KM, Wolf-Ringwall A, Thamm DH. Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17139
BibTeX
@article{Parker2024,
author = {Parker, Ashley S and Burton, Jenna H and Curran, Kaitlin M and Wolf-Ringwall, Amber and Thamm, Douglas H},
title = {Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17139}
}
EUVIMED